Product Description
Ara-290 specifically binds the innate repair receptor (IRR), enabling researchers to study EPO-derived tissue repair mechanisms without hematopoietic side effects.
Research demonstrates significant reduction of pro-inflammatory cytokines, supporting investigations into chronic inflammation, autoimmune response, and metabolic disorders.
Ara-290 has shown strong potential in reducing nerve inflammation and restoring nerve function in neuropathic pain models, making it valuable in neurobiology studies.
Studies highlight its ability to reduce cellular stress, enhance microvascular function, and promote healing following ischemic injury, trauma, or metabolic dysfunction.
Ara-290 provides the protective benefits of EPO signaling without affecting red blood cell production, enabling safer, targeted research applications.
Lyophilized, purified form ensures consistent biological activity in cellular and animal model experiments.
| Parameter | Description |
| CAS Number | 1208243-50-8 |
| Product Name | Ara-290 |
| Peptide Origin | EPO-derived helix-B surface peptide (HBSP) |
| Amino Acid Length | 11 amino acids |
| Appearance | White to off-white lyophilized powder |
| Storage | –20°C, avoid light and moisture |
| Specification | Details |
| Purity | ≥98% (HPLC) |
| Form | Lyophilized powder |
| Vial Sizes | 1 mg, 5 mg, 10 mg (custom options available) |
| Packaging | Sterile sealed vials, moisture-resistant packaging |
| Shelf Life | 24 months under recommended storage |
Used in studying nerve injury, diabetic neuropathy, and inflammatory neuropathies due to its ability to modulate nerve inflammation and repair pathways.
A key molecule for evaluating cytokine regulation, immune response modulation, and autoimmune condition models.
Supports research on organ protection, ischemia-reperfusion injury, wound healing, and microvascular recovery.
Explored for its protective role in metabolic dysfunction, including diabetes-associated tissue damage.
Ideal for analyzing non-erythropoietic EPO signaling through the EPOR-CD131 receptor complex.